Literature DB >> 3371839

Pharmacokinetic interaction between nifedipine and propranolol.

E Zylber-Katz1, M Turetz-Abramovitch, G Koren, M Levy.   

Abstract

In 8 healthy volunteers, single-dose nifedipine pharmacokinetics were compared with and without the coadministration of propranolol. An elevation of the mean Cmax was found, from 73.9 +/- 14.1 when nifedipine was taken alone, to 115.7 +/- 12.1 (SE) ng/ml (P less than 0.02) when the agent was combined with propranolol. The AUC0----infinity increased as well, from 287.1 +/- 33.5 to 363.0 +/- 54.3 (SE) (micrograms.hr)/l (P less than 0.01), indicating an increase in bioavailability. Propranolol treatment did not significantly affect the nifedipine half-life (alpha or beta phase) or the estimated volume of distribution, whereas systemic clearance tended to decrease in 6 of the subjects. The most likely explanation for increased bioavailability of nifedipine when coadministered with propranolol is by a reduction of the hepatic "first-pass" clearance, as a result of changes in hepatic blood flow.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3371839     DOI: 10.1111/j.1472-8206.1988.tb00618.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  2 in total

1.  Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

Authors:  D F Schoors; I Vercruysse; G Musch; D L Massart; A G Dupont
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 2.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.